<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2005257424
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        MESTINON 60MG TABLET
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        PYRIDOSTIGMINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        22.25
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="ICN Polfa Rzeszow S.A. " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            ICN Polfa Rzeszow S.A. 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 540]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ZIMMO TRADING ESTABLISHMENT
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            MEDA Pharmaceuticals Switzerland GmbH 
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N07AA02 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&ndash;&ndash;<br />Pharmacotherapeutic group:<br />This preparation inhibits the breakdown of acetylcholine, a natural transmitter substance, for example of nerve impulses to muscles. Due to this inhibition of its breakdown, the effect of acetylcholine is strengthened, which causes activation of the muscles of certain internal organs, such as those of the intestine, and an improvement in performance in the case of pathological muscle weakness. The action of Mestinon has a gentle onset, a smooth course, lasts a comparatively long time and subsides gradually.<br />&ndash;&ndash;<br />Therapeutic indications:<br />Mestinon is prescribed by a doctor for certain disorders of autonomic nervous system regulation, for example paralytic ileus and resulting constipation. In pathological muscle weakness (myasthenia gravis), Mestinon eliminates the functional disorder and relieves the symptoms.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>a. Do not take Mestinon<br />&ndash;&ndash;<br />in the case of hypersensitivity to the active substance or any of the other listed ingredients,<br />&ndash;&ndash;<br />in the case of blockage of the intestine or urinary tract.<br />b. Take special care with Mestinon<br />In the following diseases, your doctor must weigh the increased risk of undesirable effects against the benefit of the treatment with particular care:<br />&bull;<br />all conditions that are accompanied by spasm of the bronchi in the lung, such as bronchial inflammation or asthma;<br />&bull;<br />cardiac arrhythmias, such as a slow pulse (bradycardia); elderly persons tend more to arrhythmias than younger ones;<br />&bull;<br />heart failure;<br />&bull;<br />recent blockage of the coronary arteries (myocardial infarction);<br />&bull;<br />very low blood pressure;<br />&bull;<br />imbalance in the autonomic nervous system, which can be apparent as low blood pressure, slow pulse, constricted pupils, cold hands and feet and lethargy (vagotonia);<br />&bull;<br />kidney disease;<br />&bull;<br />stomach ulcer;<br />&bull;<br />after gastrointestinal operations;<br />&bull;<br />epilepsy and Parkinson&rsquo;s disease;<br />&bull;<br />overactivity of the thyroid gland;<br />&bull;<br />diabetes.<br />It is important that you keep to the prescribed dosage. If you experience increased muscle weakness, you should contact your doctor immediately.</p><p>c. Taking other medicines, herbal or dietary supplements<br />Tell your doctor if you are taking other medicines at the same time or are being treated with them, such as<br />&bull;<br />certain medicines that inhibit the body&rsquo;s immune defences (immunosuppressant drugs or steroid preparations),<br />&bull;<br />certain medicines that relax the muscles in the gastrointestinal tract,<br />&bull;<br />certain muscle-relaxant drugs,<br />&bull;<br />certain antibiotics, certain anaesthetics, certain medicines against heart arrhythmias, certain medicines that affect the transmission of nerve impulses to muscles.<br />d. Pregnancy and breast-feeding<br />On the basis of experience to date, there is no known risk for the baby with correct use. However, systematic scientific studies were never conducted. As a precaution, you should avoid medicines as much as possible during pregnancy and breast-feeding or ask your doctor or pharmacist for advice.<br />e. Driving and using machines<br />This medicine can interfere with the ability to react, drive and operate tools or machines.<br />f. Important information about some of the ingredients of Mestinon<br />Patients with rare hereditary problems like galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption should not take Mestinon 10mg tablets.<br />Patients with rare hereditary problems like fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase deficiency should not take Mestinon 60mg sugar-coated tablets.<br />Tell your doctor or pharmacist if you<br />&ndash;&ndash;<br />suffer from other diseases,<br />&ndash;&ndash;<br />have allergies or<br />&ndash;&ndash;<br />take other medicines (including medicines purchased without a prescription) or use them externally.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep strictly to your doctor&rsquo;s dosage instructions. Swallow the tablets or sugar-coated tablets whole and drink about half a glass of water after them. If you have difficulties with swallowing, it is advisable to take them when sitting up or standing. After taking Mestinon the full effect usually occurs within 15&ndash;30 minutes.<br />To treat intestinal sluggishness, the doctor will advise you, for example, to take one sugar-coated tablet every four hours during the day.<br />In myasthenia gravis, the dosage and dose frequency must be adjusted by the doctor to your particular situation. At rest, for example, while you are asleep, the effect of Mestinon lasts longer than during physical activity. Thus 1&ndash;3 sugar-coated tablets are needed about every four hours during the day while a dose taken at bedtime usually suffices during the night.<br />If Mestinon has to be used to treat children, the age-appropriate dosage must be established by the doctor and the corresponding dose strength must be prepared individually from the tablets (e.g. in a hospital pharmacy). In children, the doctor&rsquo;s dosage instructions must be followed particularly strictly.<br />If you do not respond as expected to Mestinon, this can be due to the dosage being too low, but sometimes also to the dosage being too high. In such cases, ask your doctor.<br />Do not change the prescribed dosage on your own initiative. If you think that the effect of the medicine is too weak or too strong, talk to your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Mestinon can cause side effects, although not everybody gets them.<br />The following side effects can occur when Mestinon is taken:<br />Allergies (drug hypersensitivity), nausea, vomiting, increased intestinal activity including stomach discomfort (for e.g. pain, cramps etc) or diarrhoea, increased sputum, saliva and tears, visual disturbances, muscle cramps, muscle twitches and muscle weakness, diminished muscle tension, cardiac arrhythmias, such as slow or fast pulse, low blood pressure, coronary vessel spasm (Prinzmetal angina), fainting, breathing problems with pre-existing lung disease, skin rash, increased sweating, urinary urgency and psychiatric disorders in patients with previous psychiatric problems. Talk to your doctor if you have these side effects for the first time or if they get worse.<br />If you notice side effects not described here, you should tell your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The medicine should be kept in the closed original pack, store below 30&deg;C, and out of the reach of children.<br />The medicine must not be used after the date identified by &ldquo;EXP&rdquo; on the package.<br />Your doctor or pharmacist will provide you with further information as they have detailed professional information about this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>a. What Mestinon contains:<br />1 tablet (white) contains 10 mg pyridostigmine bromide as active substance and also lactose and other excipients.<br />1 sugar-coated tablet (orange) contains 60 mg pyridostigmine bromide as active substance and also sucrose and other excipients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Tablets containing 10mg: 50, 100, 250
Sugar-coated tablets containing 60mg: 20, 150
Not all pack sizes may be marketed
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorisation Holder<br />MEDA Pharmaceuticals Switzerland GmbH<br />8602 Wangen-Br&uuml;ttisellen, Switzerland</p><p>Manufacturer of Mestinon&reg; 10mg tablet<br />Labiana Pharmaceuticals S.L.U<br />Casanova 27-31<br />08757-Corbera de LIobregat<br />(Barcelona), Spain<br />Manufacturer of Mestinon&reg; 60mg sugar-coated tablet<br />ICN Polfa Rzeszow S.A.<br />Ul. Przemyslowa 2<br />Reszow, Poland</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                June 2016.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>&ndash;مجموعة المعالجة الدوائية:&ndash;<br />لض&brvbar;، وهي مادة طبيعية ناقلة، على سبيل المثال نقل النبضات العصبية للعضات. وتتم تقوية تأثي&iquest; تفكك أسيتيل الكولين&Aacute;يمنع هذا المستح لللللللف&Atilde; اأداء ي&iquest; بسبب منع تفككه، مما يسبب تنشيط عضات بعض اأعضاء الداخلية مثل عضات اأمعاء، باإضافة إى تحسين&iquest;أسيتيل الكولينة طويلة نسبيًا ويخف تدريجيًا.لض&brvbar;. يبدأ ميستينون بلطف وله دورة سلسة ويستمر لفت&Egrave;حالة الضعف العضي المري&ndash; دواعي الاستعمال العلاجية:&ndash;<br />المستقل، على سبيل المثال، العلوص الشلي واإمساك للليصف الطبيب ميستينون لعاج اضطرابات معينة خاصة بتنظيم الجهاز العصبي )الوهن العضي الوبيل(، يلغي ميستينون الاضطراب الوظيفي ويخفف من اأعراض.لللض&Egrave;الناتج عنه. وفيما يخص ضعف العضات المري</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>ا.لا تتناول ميستينون المكونات،ل&ndash;<br />فف&Atilde; حالة فرط الحساسية للمادة الفعالة أو أي من المواد اأخرى المدرجة ي&Atilde;&ndash;يحالة انسداد اأمعاء أو المسالك البولية.ل&ndash;<br />ف&Atilde;&ndash;يب.تعامل بعناية مع ميستينون مقابل منافع العاج:لللفف&Atilde; المرغوب فيها ي&brvbar; اأمراض التالية، يجب أن يقيس طبيبك بعناية زيادة مخاطر اآثار غي&Atilde;يالرئة مثل التهاب الشعب الهوائية أو الربو؛&bull;<br />فف&Atilde; الشعب الهوائية ي&Atilde; يصاحبها تشنج ي<br />كل الحالات التيل&bull;<br />ضض&brvbar;بات القلب بنسبة أكب&Ugrave;بات القلب، مثل النبض البطيء )بطء القلب(؛ يتعرض كبار السن إى عدم انتظام &Ugrave;<br />حالات عدم انتظام من اأصغر سنًا؛لالسكتة القلبية؛&bull;<br />التاجية )نوبة قلبية(؛&bull;<br />ف&iquest;ايين&nbsp;الش&Atilde;<br />انسداد حديث يضغط الدم؛&bull;<br />ف&Atilde;<br />انخفاض شديد ي&bull;<br />فف&iquest; والقدمين&iquest; وبرودة الكفين&iquest; ضغط الدم وبطء النبض وضيق بؤبؤ العين&Atilde; المستقل، والذي يمكن أن يظهر كانخفاض ي الجهاز العصبي&Atilde;<br />خلل يوالخمول )غلبة المبهم(؛أمراض الكلى؛&bull;<br />قرحة المعدة؛&bull;<br />بعد عمليات الجهاز الهضمي؛&bull;<br />الرع وداء باركنسون؛ص&bull;<br />فرط نشاط الغدة الدرقية؛&bull;<br />داء السكري.&bull;<br />ضعف العضات، يجب عليك الاتصال بطبيبك على الفور.لفز&Atilde;ت زيادة ي&brvbar;م بالجرعة الموصوفة لك. إذا اختب&brvbar;من المهم أن</p><p>ج.تناول اأدوية اأخرى أو المكمات العشبية والغذائيةللل تتناولها بالفعل، مثللف نفس الوقت أو باأدوية التي&Atilde; طبيبك قبل تناول أي أدوية أخرى ي&brvbar;أخبويد(،لل&bull;<br />&brvbar; تمنع الدفاعات المناعية للجسم )اأدوية المثبطة للمناعة أو تركيبات الستي<br />بعض اأدوية التيالقناة الهضمية،لل&bull;<br />ف&Atilde; تعمل على ارتخاء العضات ي<br />بعض اأدوية التيتعمل على ارتخاء العضاتلل&bull;<br /><br />بعض اأدوية التيتؤثر على انتقال لل&bull;<br />ضبات القلب، وبعض اأدوية التي&Ugrave;<br />بعض المضادات الحيوية، وبعض اأدوية المخدرة، وبعض أدوية عدم انتظام النبضات العصبية للعضات.لد.الحمل والرضاعة اآن. ومع ذلك، لم يتم إجراء أي دراسات علمية منهجية. ل مع الاستخدام الصحيح وفقًا للتجارب حت&iquest;لا توجد مخاطر معروفة على الجنين، أو طلب النصيحة من الطبيب أو الصيديل.للئ&agrave;عليك تجنب اأدوية بقدر اإمكان أثناء الحمل والرضاعة كإجراء وقايه.القيادة واستخدام اآلاتل يمكن أن يتدخل هذا الدواء مع القابلية لاستجابة والقيادة وتشغيل اآلات واستخدام اأدوات.لللو.معلومات هامة حول بعض مكونات ميستينون الذين يعانون من المشاكل الوراثية مثل عدم تحمل الغاكتوز أو نقص الاكتاز أو سوء للض&Egrave;لا يجب تناول أقراص ميستينون 10 ملغ عند المر الذين يعانون من المشاكل الوراثية مثل لض&Egrave;امتصاص الغلوكوز-الغاكتوز. لا يجب تناول أقراص ميستينون المغلفة بالسكر 60 ملغ عند المر عدم تحمل الفركتوز أو سوء امتصاص الغلوكوز-الغاكتوز أو نقص السكراز-إيزومالتاز. لطبيبك أو الصيديل إذا&brvbar;أخبمن أمراض أخرى،&ndash;<br />&agrave;&ndash;كنت تعاني&ndash;كانت لديك حساسية أو&ndash;<br />لا تحتاج لوصفة طبية( أو إذا كنت تستخدمها بشكل خارجي.ل&ndash;<br />&ndash;كنت تتناول أدوية أخرى )تتضمن اأدوية</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>حوايل نصف كوب من الماء بعدها. إذا واجهت للز&auml;م بشدة بإرشادات طبيبك للجرعة. ابتلع اأقراص أو اأقراص المغلفة بالسكر كاملة واش&brvbar;الت30 دقيقة.لفف- غضون 15&Atilde; الكامل لميستينون غالبًا ي&brvbar; البلع، يُنصح بتناول اأقراص أثناء الجلوس باعتدال أو الوقوف. يظهر التأثي&Atilde;صعوبات يلمعالجة خمول اأمعاء، سينصحك الطبيب، على سبيل المثال، بتناول قرص واحد مغلف بالسكر كل أربعة ساعات أثناء النهار.ل لفف&Atilde; حالة الوهن العضي الويبل، يجب تعديل الجرعة ومرات تكرارها بواسطة الطبيب لتناسب حالتك. ففي أوقات الراحة على سبيل المثال، ي&Atilde;ي3 أقراص مغلفة بالسكر كل حوايل أربعة ساعات -. لذلك، تحتاج من 1&agrave;ة أطول من أوقات النشاط البدني&brvbar; ميستينون لفت&brvbar;وقت النوم يستمر تأثيخال النهار، بينما غالبًا ما تكون جرعة واحدة عند وقت النوم كافية أثناء الليل.ل قوة الجرعة ل&brvbar;إذا كان يجب استخدام ميستينون لمعالجة اأطفال، فيجب تحديد الجرعة المناسبة حسب السن بواسطة الطبيب ويجب تحضي المستشفى(. عند اأطفال، يجب اتباع إرشادات الطبيب للجرعات بشكل صارم.للف&Atilde;المناسبة من اأقراص بشكل منفصل )على سبيل المثال، ي مثل هذه الحالات، اسأل لفف&Atilde; بعض اأحيان لزيادة الجرعة. ي&Atilde;إذا لم تستجب لميستينون كما هو متوقع، يمكن أن يرجع ذلك لقلة الجرعة، أو يطبيبك.من الازم، تحدث مع طبيبك أو الصيديلي</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل كل اأدوية، يمكن أن يسبب ميستينون أثارًا جانبية ولكنها لا تحدث للجميع.ليمكن أن تحدث اأثار الجانبية التالية عند تناول ميستينون:ل المعدة )على ف&Atilde;الحساسية )فرط الحساسية تجاه الدواء(، والغثيان، والقيء، وزيادة النشاط المعوي بما يتضمن الشعور بعدم الراحة يسبيل المثال، اأآم والتقلصات( أو اإسهال، وزيادة البلغم واللعاب والدموع، والاضطرابات البرية، وتشنجات العضات، وضعف صللللالعضات، والتقليل من توتر العضات، اختال نبض القلب مثل النبض البطيء أو الريع، وانخفاض ضغط الدم، وتشنج اأوعية التاجية سلللل)ذبحة برنزميتال( واإغماء، ومشاكل التنفس المرتبطة بأمراض الرئة الموجودة من قبل، والطفح الجلدي، وزيادة التعرق، واإلحاح البويل، للت هذه اأثار الجانبية أول مرة أو إذا للففض&brvbar; السابق. تحدث مع طبيبك إذا اختب&Atilde; بمشاكل نفسية ي&iquest; المصابين&Egrave; المر&Atilde;والاضطرابات النفسية يساءت حالتها.موصوفة هنا، يجب عليك إخبار الطبيب أو الصيديلي&brvbar;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>درجة حرارة أقل من 30 درجة مئوية وبعيدًا عن متناول اأطفال.للفف&Atilde; العلبة اأصلية المغلقة، ويتم تخزينه ي&Atilde;يجب أن يتم حفظ الدواء&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>أ.مكونات ميستينون: فعالة.لللل&brvbar; بروميد كمادة فعالة باإضافة إى الاكتوز ومواد أخرى غي&iquest;يدوستجمين&brvbar;يحتوي القرص )اأبيض( على 10 ملغ من بيفعالة.لل&brvbar; بروميد كمادة فعالة باإضافة إى السكروز ومواد أخرى غي&iquest;يدوستجمين&brvbar;تقايل( على 60 ملغ من بي&brvbar;يحتوي القرص المغلف بالسكر )</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>ب.محتويات العلبة: 250ل ،100 ، تحتوي على 10ملغ: 50اأقراص التي150ل ، تحتوي على 60ملغ: 20اأقراص المغلفة بالسكر التيلم يتم تسويق جميع أحجام العبوات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>خيص بالتسويق والش&brvbar;ج.حامل التخيص بالتسويق&brvbar;حامل التMEDA Pharmaceuticals Switzerland GmbH<br />Switzerland ،Wangen-Br&uuml;ttisellen 8602</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            06/2016
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                MESTINON 60mg sugar-coated tablets (dragées)
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Active ingredient: 60 mg pyridostigmine bromide
Excipients: For a full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                sugar-coated tablet
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Intestinal atony, atonic constipation. Myasthenia gravis.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adults<br />Intestinal atony, atonic constipation<br />1 sugar-coated tablet a required, e.g. at intervas of 4 hours.<br />Central and peripheral pareses (dose-finding)<br />1-6 sugar-coated tablets daily depending on the severity of the patient&rsquo;s condition.<br />Myasthenia gravis<br />1-3 sugar-coated tablets 2-4 times daily, or higher doses if required.<br />Special dosage instructions<br />It is important to remember that the full effect of the treatment appears gradually, usually within 15-30 minutes.<br />Elderly patients<br />No special dosage instructions.<br />Patients with hepatic impairment<br />No special dosage instructions.<br />Patients with renal impairment<br />Pyridostigmine is mainly excreted unchanged through the kidneys. In patients with renal disease associated with impaired renal clearance, lower doses may therefore be indicated. The dose should always be ad-justed to the effect.<br />Children<br />The 10-mg tablet is not suitable for use in paediatric patients. The age-appropriate dosage strength should<br />be prepared individually under GMP conditions (in the hospital&#39;s pharmacy, for instance).<br />The required dose must be carefully titrated when used in paediatrics.<br />In cases of neonatal myasthenia, treatment with neostigmine (Prostigmin) is generally preferred. However,<br />if this appears unsuitable due to excessive cholinergic side effects, then Mestinon can be administered. In<br />these cases, the following recommendation serves as a rough guideline: every 4-6 hours S mg per os in the<br />form of the appropriately prepared tablet dose, 30-60 minutes before meals. This dose should be gradually<br />reduced until the medication can be withdrawn..</p><p>Treatment beyond the eighth week of life is required only in extremely rare cases of congenital and familial<br />infantile myasthenia.<br />Myasthenia gravis<br />In myasthenia gravis, one dose is effective for approximately four hours during the day whilst, at night (ow-ing to reduced physical activity), a longer duration of effect of around 6 hours can be expected.<br />It is recommended that the times of administration be chosen so that the maximum effect coincides with the most strenuous physical exertion, e.g. when getting up and at mealtimes.<br />Because of the similarity of clinical symptoms when the product is ineffective (myasthenic crisis) or in case of overdose (cholinergic crisis), investigation with a suitable test (e.g. with edrophonium chloride), consid-ering the necessary precautions, is required after a higher dose, if the corresponding symptoms occur.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the listed excipients.
In the presence of mechanical obstruction of the ntestinal or urinary tract.
Mestinon should not be given in combination with depolarising muscle relaxants, such as suxamethonium.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Great caution is required when Mestinon is given to patients with obstructive lung disease such as bron-chial asthma or chronic obstructive pulmonary disease (COPD). Caution is also required in the case of car-diac arrhythmias such as bradycardia and atrioventricular block (elderly patients may tend more to arrhyth-mias than young adults); decompensated heart failure; recent coronary occlusion; hypotension; vagotonia; renal disease; gastric ulcer; gastrointestinal surgery; epilepsy or parkinsonism; hyperthyroidism; diabetes mellitus.<br />If relatively high doses are taken by myasthenia gravis patients, administration of atropine or other anticho-linergic agents may be necessary to counteract the muscarinic effect.<br />The possibility of a &ldquo;cholinergic crisis&rdquo; because of a pyridostigmine bromide overdose must be distinguished from a &ldquo;myasthenic crisis&rdquo; because of worsening of the disease in the differential diagnosis in all patients. Both types of crisis are expressed as increased muscle weakness. However, while the anticholinesterase treatment must be increased in a myasthenic crisis, the treatment must be discontinued immediately with a cholinergic crisis and suitable supportive measures, including respiratory support, must be instituted.<br />Mestinon is mainly excreted unchanged through the kidneys. Mestinon should therefore be used with cau-tion in renal failure. Lower doses may therefore be required for patients with renal disease. The required dose should be determined individually according to the effect.<br />Mestinon should be used with caution if suxamethonium chloride is present in high overdosage as, instead of the desired abolishing of the neuromuscular blockade, this may be intensified.<br />The Mestinon requirement may be diminished following thymectomy.<br />Patients with rare hereditary problems such as fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase deficiency should not take this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Drugs with an immunosuppressive action<br />The required dose of Mestinon may be reduced with concomitant administration of drugs such as steroids or immunosuppressants. Neverthertheless, a new addition of corticosteroids may initially aggravate the symptoms of myasthenia gravis.<br />Methylcellulose</p><p>Methylcellulose inhibits the absorption of pyridostigmine bromide. Concomitant administration of medici-nal products that contain methyl cellulose as an excipient should therefore be avoided.<br />Drugs with an antimuscarinic action<br />Atropine and scopolamine counteract the muscarinic effect of pyridostigmine. It should be noted that the diminished gastrointestinal mobility caused by these drugs can delay the absorption of pyridostigmine bro-mide.<br />Muscle relaxants<br />Pyridostigmine bromide antagonises the action of curare-type non-depolarising muscle relaxants (e.g. pan-curonium and vecuronium). Pyridostigmine bromide can prolong the effect of the depolarising muscle re-laxant suxamethonium (see &ldquo;Special warnings and precautions&rdquo;).<br />Other interactions<br />Aminoglycoside antibiotics, local and some systemic anaesthetics, antiarrhythmic agents and other drugs that influence neuromuscular transmission can interact with pyridostigmine bromide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Fertility<br />Nonclinical investigations in rats have not shown any negative effects on reproductive behavior<br />Pregnancy<br />The safet of pyridostigmine bromide during pregnancy and lactation has not been studied.<br />Although the potential risk for mother and child must be weighed against the potential benefit in every case, experience to date of administration of pyridostigmine bromide to pregnant patients with myasthenia gravis has not shown any negative effects of the drug on the course of the pregnancy.<br />As the severity of myasthenia gravis often fluctuates considerably in pregnancy, particular care is required to avoid cholinergic crisis due to overdose.<br />Pyridostigmine crosses the placental barrier. Excessively high doses of pyridostigmine during pregnancy should be avoided and the newborn should be examined for possible side effects.<br />In animal studies of developmental toxicity in rats and rabbits, pyridostigmine bromide did not show any teratogenic effects after oral administration. By contrast, in the maternal toxic dose range, there was an increased rate of absorption and delayed ossification in the foetuses. In a peri- and postnatal study in rats, the weight gain in the offspring of treated mothers was reduced (see &ldquo;Preclinical data&rdquo;).<br />Intravenous use of pyridostigmine bromide can trigger uterine contractions (especially when used at the end of pregnancy). Whether there is also a risk of triggering premature labour with oral use is unknown.<br />During pregnancy, this medication should only be used strictly as indicated after a thorough consideration of the benefit-risk relationship, with careful dosing and under medical supervision.<br />Lactation<br />There is insufficient information on whether pyridostigmine bromide has effects on newborns and infants. Observations indicate that only negligible amounts of pyridostigmine bromide pass into breast milk. If treatment is required, the baby should be monitored for possible effects or should be weaned.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No study results are available in this regard.<br />In case of inadequate compensation of the underlying disease or parasympathicotonic effects after a rela-tive overdose of Mestinon/Mestinon retard (miosis, disorders of accommodation), visual acuity and there-fore the ability to react and drive and use machines may be impaired.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Like all cholinergic drugs, Mestinon can have undesirable functional effects on the autonomic nervous sys-tem.<br />Muscarine-type side effects can manifest themselves as nausea, vomiting, diarrhoea, stomach cramps, in-creased peristalsis and bronchial secretion, salivation and lacrimation as well as bradycardia and miosis. Nicotine-type side effects consist mainly of muscle spasms, muscle twitches and muscle weakness.<br />Within the organ system, the undesirable effects are listed according to the following frequencies:<br />very common (&gt;1/10), common (&lt;1/10, &gt;1/100), uncommon (&lt;1/100, &gt;1/1000), rare (&lt;1/1000, &gt;1/10,000), very rare (&lt;1/10,000). Frequency unknown (cannot be estimated from the available data) The following un-desirable effects were observed. However, their frequency is unknown.<br />Immune system disorders<br />Frequency unknown: Drug hypersensitivity<br />Psychiatric disorders<br />Frequency unknown: In the presence of organic brain changes, psychopathological symptoms including psychosis can occur during treatment with Mestinon or pre-existing symptoms may be increased.<br />Nervous system disorders<br />Frequency unknown: Syncope<br />Eye disorders<br />Frequency unknown: miosis, increased lacrimation, accommodation disorders. (e.g. blurred vision)<br />Cardiac disorders<br />Frequency unknown: arrhythmia (including bradycardia, tachycardia, AV block), Prinzmetal angina<br />Vascular disorders<br />Frequency unknown: Flushing, hypotension (see &ldquo;Overdose&rdquo;)<br />Respiratory, thoracic and mediastinal disorders<br />Frequency unknown: increased bronchial secretion in combination with bronchial obstruction.<br />Gastrointestinal disorders<br />Frequency unknown: nausea, vomiting, diarrhoea, abdominal symptoms (e.g. discomfort pain, cramps etc.), increased peristalsis, increased salivation.<br />Skin and subcutaneous tissue disorders<br />Rare: rash<br />Frequency unknown: hyperhidrosis. urticaria<br />Like other bromine-containing medications, Mestinon can lead in rare cases to rashes, which usually disap-pear rapidly after the drug is discontinued. Further use of Mestinon or other bromine-containing prepara-tions is then contraindicated.<br />Musculoskeletal and connective tissue disorders<br />Frequency unknown: increased muscle weakness, muscle twitches, tremor and muscle cramps, diminished muscle tone.<br />Renal and urinary disorders<br />Frequency unknown: increased urinary urgency.</p><p>As the symptoms may be signs of a cholinergic crisis, the treating doctor should be consulted without delay so that the cause of the symptoms and signs can be investigated (see &ldquo;Overdose&rdquo;).</p><p>To reports any side effect(s):<br />Saudi Arabia:<br />&bull; The National Pharmacovigilance Centre (NPC):<br />- Fax: +966-11-205-7662<br />- Call NPC at +966-11-2038222, Ext 2317-2356-2340<br />- SFDA Call Center: 19999<br />- E-mail: npc.drug@sfda.gov.sa<br />- Website: https://ade.sfda.gov.sa/<br />Other GCC States:<br />o Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>4.9 Overdose<br />Pyridostigmine may cause cholinergic crisis. The signs of overdose due to muscarinic effects can include abdominal cramps, increased peristalsis, diarrhoea, diaphoresis, nausea, vomiting, increased bronchial se-cretion, bronchospasm, salivation, hyperhidrosis and miosis.<br />Nicotinic side effects are expressed as muscle cramps, muscle twitches and general weakness including pa-ralysis, which may produce apnoea and cerebral anoxia in particularly severe cases. Hypotension including cardiovascular collapse and bradyarrhythmia including cardiac arrest can also occur.<br />Central nervous system effects can include excitation, confusion, slurred speech, nervousness, irritation and visual hallucinations. Convulsions and coma may occur. Countermeasures consist of the immediate dis-continuation of Mestinon or other cholinergic agents. Artificial ventilation should be initiated if there is se-vere respiratory depression. 1-2 mg atropine sulphate is given slowly intravenously as a specific antidote. If necessary, this dose can be repeated at intervals of 5 to 30 minutes.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>5.1 Pharmacodynamic properties<br />ATC code: N07AA02<br />Pyridostigmine, the active ingredient of Mestinon, is a cholinesterase inhibitor. It is characterised by the gentle onset, smooth course, comparatively long duration and gradual decline of its cholinergic action.<br />Pyridostigmine has an antagonistic effect on non-depolarising muscle relaxants only. It has a synergistic ef-fect on depolarising muscle relaxants.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption<br />Peroral pyridostigmine bromide was poorly absorbed (by about 22-25%). The rate and extent of absorption show wide inter-individual differences.<br />When administered in healthy volunteers at oral daily doses of 120 mg, 120-370 mg, and 180-1440 mg the oral bioavailability of pyridostigmine bromide was 7.6%, 18.9%, and 3-4% with Cmax of 40-80 &mu;g/L, 20-100 &mu;g/L, and 180 &mu;g/L at tmax of 3-4 h, 1.5-6 h, and 1.5 h, respectively. This low and highly variable bioavaila-bility across studies is attributed to the low absorption rate of pyridostigmine. In patients with myasthenia gravis, oral bioavailability may decrease to 3.3%.<br />Distribution<br />Peak plasma concentrations are reached approximately 1&frac12;-2 hours after administration of 120 mg pyri-dostigmine in the fasting state. The increase in active substance is delayed when taken with food.<br />The distribution volume averages 1.4 l&middot;kg -1 of body weight after intravenous administration.<br />Pyridostigmine is not noticeably bound to plasma proteins and does not cross the blood-brain barrier.</p><p>With myasthenia gravis, blood plasma levels of 20-60 ng&middot;ml -1 are required in order to obtain the desired therapeutic effect.<br />The concentration of pyridostigmine in breast milk has been found to be 36 to 113% compared to maternal plasma, which implies a very low dose to the nursing infant (about 0.1% of the dose per kilogram body-weight taken by the mother).<br />Metabolism<br />Pyridostigmine is metabolized only to a small extent. It is hydrolised by plasma cholinesterases. The main metabolite of pyridostigmine is the hydrolysis product 3-hydroxy-N-methyl-pyridinium<br />Elimination<br />Mean values of around 1.5 hours are given for the elimination half-life. This can, however, be prolonged up to three times over in individual cases. Mean plasma clearance in healthy subjects is given as 0.36- 0.65 l&middot;kg-1&middot;h-1. No confirmed data are available regarding the potential accumulation of unchanged pyri-dostigmine or active metabolites. Since the dosage must, in any case, be adjusted individually, this point is devoid of practical significance. Pyridostigmine is largely (75-81%) eliminated unchanged via the kidneys. One part (18-21%) appears as the 3-hydroxy-N-methyl-pyridine metabolite in the urine. Other unidentified metabolites account for 1-4%.<br />Kinetics in specific patient populations<br />Impaired liver function has no relevant effect on the kinetics of pyridostigmine. In the case of age- or dis-ease-induced renal failure, the elimination half-life can increase approximately four-fold; plasma clearance can be reduced to approximately one-fifth.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Subcutaneous injection of pyridostigmine bromide to rats in toxic dosages leads to salivation, twitching, tremor and respiratory difficulties, among other things. With p.o. administration of toxic doses, the rats died of acute respiratory failure. Damage to the neuromuscular synapses of the diaphragm was detectable histologically. Longer-term oral administration to rats led to inhibition of plasma cholinesterase and eryth-rocyte acetylcholinesterase.<br />In rats, an inhibition of acetylcholinesterase in erythrocytes with tremor was noted after three months of treatment with &ge; 15 mg/kg. At 60 mg/kg, mortality amounted to 10% of animals treated. Clinicochemical changes were also found in this group. Treatment-related haematology, post-mortem or histopathology findings occurred in none of the dosage groups.<br />Standard in-vitro and in-vivo tests of genetic toxicology yielded no evidence of a clinically relevant geno-toxic potential of pyridostigmine bromide.<br />Preclinical studies on the carcinogenicity of pyridostigmine bromide were not conducted.<br />Animal studies on the reproductive toxicity of pyridostigmine bromide were conducted in rats after oral administration. No effects on male and female fertility were seen. At high doses, post-implantation losses were noted, possibly caused by the cholinergic stimulation of the maternal animals. In studies on develop-mental toxicity, there was an increased resorption rate in rats and rabbits after oral administration in the maternal toxic dose range and delayed ossification in the rat foetuses. In a peri-/postnatal study in rats, the weight gain in the progeny of treated maternal animals was reduced.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Excipients:<br />Maize starch:<br />23.200 mg / tablet<br />Magnesium stearate:<br />0.800 mg/ tablet<br />Pregelatinised starch:<br />7.500 mg/ tablet<br />Povidone K30:<br />20.000 mg/ tablet<br />Silica, colloidal anhydrous:<br />42.500 mg/ tablet<br />Talc:<br />6.000 mg/ tablet<br />Coating components:<br />Acacia spray-dried gum:<br />1.473 mg/ tablet<br />Iron oxide red (E 172) CI 77491:<br />0.010 mg/ tablet<br />Iron oxide yellow (E 172) CI 77492:<br />0.006 mg/ tablet<br />Light liquid paraffin:<br />0.008 mg/ tablet<br />Hard paraffin:<br />0.047 mg/ tablet<br />Rice starch:<br />14.583 mg/ tablet<br />Sucrose crystalline:<br />161.569 mg/ tablet<br />Talc:<br />12.304 mg/ tablet</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years
This preparation must not be used after the date identified by “EXP.” on the packaging.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in closed original packaging at store below 30&deg;C and out of the reach of children.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Packed in glass bottle &amp; PE Screw cap<br />Sugar-coated tablets containing 60 mg: 20</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                MEDA Pharmaceuticals Switzerland GmbH, 8602 Wangen-Brüttisellen, Switzerland
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                January 2016
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>